BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting chronic and acute bacterial infections. The company became publicly listed in October 2019 following its business combination with Chardan NexTech Acquisition Corp, a SPAC sponsored by Chardan Capital Markets that completed its IPO in 2018. BiomX operates in the biotechnology and infectious-disease sector, advancing a proprietary phage therapy platform with programs targeting conditions including diabetic foot osteomyelitis. The company filed an 8-K/A amendment with the SEC on September 1, 2026, under accession number 0001213900-26-096272. Visit SpacDesk and sign up for full data, filings history, and analytics on BiomX and hundreds of other SPAC-originated companies.